Pamisel, H1 Sales of 25.9 Billion KRW and Operating Profit of 4.8 Billion KRW 'Record High Performance'

[Asia Economy Reporter Hyungsoo Park] Pharmicell announced on the 17th that its sales in the first half of the year reached 25.9 billion KRW, a 24% increase compared to the same period last year. During the same period, operating profit was 4.8 billion KRW and net profit was 4.1 billion KRW, achieving the highest performance in the company's history.

The Chemical Division continued its sales growth with a more than 29% increase in sales compared to the same period last year. The Chemical Division recorded sales of 25.3 billion KRW and operating profit of 8.1 billion KRW in the first half, also achieving its best performance ever. By product category, sales of active pharmaceutical ingredients (nucleosides, mPEG) reached 11.1 billion KRW, and sales of advanced materials related to 5G reached 7.5 billion KRW, driving the Chemical Division's performance growth.

A company official stated, "In the first half of this year, sales of all products in the Chemical Division, including high value-added products such as active pharmaceutical ingredients and advanced materials related to 5G, increased," and added, "For active pharmaceutical ingredients, orders from existing customers continue to grow, so sales growth is expected to continue in the second half."

He continued, "Ongoing clinical trials for the chronic kidney disease treatment ‘Selgram-CKD’ and liver cirrhosis treatments are also expected to proceed smoothly, supported by the Chemical Division's sustained growth."

This content was produced with the assistance of AI translation services.